A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 05 May 2025
At a glance
- Drugs CC 94676 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
Most Recent Events
- 28 Apr 2025 According to a Florida Cancer Specialists & Research Institute media release, abstract of this study published in the Journal of Oncology.
- 28 Apr 2025 According to a Florida Cancer Specialists & Research Institute media release, Manish R. Patel, MD was the oral presenter of an abstract analyzing the results of the first in-human study at the annual American Urology Association meeting.
- 28 Apr 2025 Results (n=20) presented in the Florida Cancer Specialists & Research Institute Media Release.